Effects of a Behavioral Weight Loss Intervention and Metformin Treatment on Serum Urate: Results from a Randomized Clinical Trial

Jiun-Ruey Hu, Hsin-Chieh Yeh, Noel T Mueller, Lawrence J Appel, Edgar R Miller 3rd, Nisa M Maruthur, Gerald J Jerome, Alex R Chang, Allan C Gelber, Stephen P Juraschek, Jiun-Ruey Hu, Hsin-Chieh Yeh, Noel T Mueller, Lawrence J Appel, Edgar R Miller 3rd, Nisa M Maruthur, Gerald J Jerome, Alex R Chang, Allan C Gelber, Stephen P Juraschek

Abstract

Background: Lower body mass index (BMI) has been associated with lower serum urate (SU), but only in observational studies. We sought to determine the effects of behavioral weight loss and metformin treatment on SU in a randomized trial. Methods and Findings: The Survivorship Promotion In Reducing IGF-1 Trial (SPIRIT) was a parallel three-arm randomized controlled trial of overweight/obese adult cancer survivors without gout at a single center in Maryland, United States. Participants were randomized to: (1) coach-directed weight loss (behavioral telephonic coaching), (2) metformin (up to 2000 mg daily), or (3) self-directed weight loss (informational brochures; reference group). SU and BMI were assessed at baseline and at 3, 6, and 12 months post-randomization. The 121 participants had a mean ± standard deviation (SD) age of 60 ± 9 years, 79% were female, and 45% were Black. At baseline, BMI was 35 ± 5 kg/m2, and SU was 5.6 ± 1.3 mg/dL. Compared to the self-directed group, at 12 months, the coach-directed group reduced BMI by 0.9 kg/m2 (95% confidence interval (CI): -1.5, -0.4) and metformin reduced BMI by 0.6 kg/m2 (95% CI: -1.1, -0.1). However, compared to the self-directed group, the coach-directed group unexpectedly increased SU by 0.3 mg/dL (95% CI: 0.05, 0.6), and metformin non-significantly increased SU by 0.2 mg/dL (95% CI: -0.04, 0.5); these effects were attenuated when analyses included change in estimated glomerular filtration rate (eGFR). Conclusions: In this randomized trial of cancer survivors without gout, reductions in BMI either increased or did not change SU, potentially due to effects on eGFR. These results do not support a focus on BMI reduction for SU reduction; however, long-term studies are needed. ClinicalTrials.gov Registration: NCT02431676.

Keywords: metformin; randomized clinical trial; serum urate; uric acid; weight loss.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(A) Mean body mass index (BMI, in kg/m2) and (B) mean serum urate level (SU, in mg/dL) (C) mean estimated glomerular filtration rate (eGFR, in mL/min/1.73 m2) of SPIRIT study participants at baseline, 3 months, 6 months, and 12 months, by treatment arm—SD (self-directed weight loss), CD (coach-directed weight loss), or met (metformin). Other abbreviations: CI: confidence interval; eGFR: estimated glomerular filtration rate.

References

    1. Kuo C.-F., Grainge M.J., Zhang W., Doherty M. Global epidemiology of gout: Prevalence, incidence and risk factors. Nat. Rev. Rheumatol. 2015;11:649–662. doi: 10.1038/nrrheum.2015.91.
    1. Neogi T. Gout. N. Engl. J. Med. 2011;364:443–452. doi: 10.1056/NEJMcp1001124.
    1. Juraschek S.P., Miller E.R., Gelber A.C. Body Mass Index, Obesity, and Prevalent Gout in the United States in 1988–1994 and 2007–2010. Arthritis Care Res. (Hoboken) 2013;65:127–132. doi: 10.1002/acr.21791.
    1. Bhole V., de Vera M., Rahman M.M., Krishnan E., Choi H. Epidemiology of gout in women: Fifty-two–year followup of a prospective cohort. Arthritis Rheum. 2010;62:1069–1076. doi: 10.1002/art.27338.
    1. Maynard J.W., DeMarco M.A.M., Baer A.N., Köttgen A., Folsom A.R., Coresh J., Gelber A.C. Incident Gout in Women and Association with Obesity in the Atherosclerosis Risk in Communities (ARIC) Study. Am. J. Med. 2012;125:717.e9–717.e17. doi: 10.1016/j.amjmed.2011.11.018.
    1. Choi H.K., Atkinson K., Karlson E.W., Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: The health professionals follow-up study. Arch. Intern. Med. 2005;165:742–748. doi: 10.1001/archinte.165.7.742.
    1. Dalbeth N., Chen P., White M., Gamble G.D., Barratt-Boyes C., Gow P.J., Orr-Walker B. Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: A prospective longitudinal study. Ann. Rheum. Dis. 2014;73:797–802. doi: 10.1136/annrheumdis-2013-203970.
    1. Dessein P.H., Shipton E.A., Stanwix A.E., Joffe B.I., Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: A pilot study. Ann. Rheum. Dis. 2000;59:539–543. doi: 10.1136/ard.59.7.539.
    1. Nanji A.A., Freeman J.B. Rate of weight loss after vertical banded gastroplasty in morbid obesity: Relationship to serum lipids and uric acid. Int. Surg. 1985;70:323–325.
    1. Nicholls A., Scott J.T. Effect of weight-loss on plasma and urinary levels of uric acid. Lancet. 1972;300:1223–1224. doi: 10.1016/S0140-6736(72)92271-4.
    1. Richette P., Poitou C., Manivet P., Denis J., Bouillot J.L., Clément K., Oppert J.M., Bardin T. Weight Loss, Xanthine Oxidase, and Serum Urate Levels: A Prospective Longitudinal Study of Obese Patients. Arthritis Care Res. 2016;68:1036–1042. doi: 10.1002/acr.22798.
    1. Williams P.T. Effects of diet, physical activity and performance, and body weight on incident gout in ostensibly healthy, vigorously active men. Am. J. Clin. Nutr. 2008;87:1480–1487. doi: 10.1093/ajcn/87.5.1480.
    1. Yamashita S., Matsuzawa Y., Tokunaga K., Fujioka S., Tarui S. Studies on the impaired metabolism of uric acid in obese subjects: Marked reduction of renal urate excretion and its improvement by a low-calorie diet. Int. J. Obes. 1986;10:255–264.
    1. Zhu Y., Zhang Y., Choi H.K. The serum urate-lowering impact of weight loss among men with a high cardiovascular risk profile: The Multiple Risk Factor Intervention Trial. Rheumatol. (Oxf.) 2010;49:2391–2399. doi: 10.1093/rheumatology/keq256.
    1. FitzGerald J.D., Dalbeth N., Mikuls T., Brignardello-Petersen R., Guyatt G., Abeles A.M., Gelber A.C., Harrold L.R., Khanna D., King C., et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol. 2020;72:879–895. doi: 10.1002/art.41247.
    1. Yokose C., McCormick N., Rai S.K., Lu N., Curhan G., Schwarzfuchs D., Shai I., Choi H.K. Effects of Low-Fat, Mediterranean, or Low-Carbohydrate Weight Loss Diets on Serum Urate and Cardiometabolic Risk Factors: A Secondary Analysis of the Dietary Intervention Randomized Controlled Trial (DIRECT) Diabetes Care. 2020;43:2812–2820. doi: 10.2337/dc20-1002.
    1. Yeh H.C., Maruthur N., Wang N.Y., Jerome G., Dalcin A., Tseng E., White K., Miller E., Juraschek S., Mueller N., et al. Obesity. Volume 28. WILEY; Hoboken, NJ, USA: 2020. A Randomized Controlled Trial of Behavioral Weight Loss and Metformin on IGFs in Cancer Survivors; p. 17.
    1. Yeh H.C., Maruthur N.M., Wang N.Y., Jerome G.J., Dalcin A.T., Tseng E., White K., Miller E.R., Juraschek S.P., Mueller N.T., et al. Effects of Behavioral Weight Loss and Metformin on Insulin-like Growth Factors in Cancer Survivors: A Randomized Trial. J. Clin. Endocrinol. Metab. 2021 doi: 10.1210/clinem/dgab266.
    1. Wolin K.Y., Colditz G.A. Can weight loss prevent cancer? Br. J. Cancer. 2008;99:995–999. doi: 10.1038/sj.bjc.6604623.
    1. Morgillo F., Fasano M., Della Corte C.M., Sasso F.C., Papaccio F., Viscardi G., Esposito G., Di Liello R., Normanno N., Capuano A., et al. Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: A multicentre, open-label phase I–II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer. ESMO Open. 2017;2:e000132. doi: 10.1136/esmoopen-2016-000132.
    1. Barskova V.G., Eliseev M.S., Kudaeva F.M., Aleksandrova E.N., Volkov A.V., Nasonova V.A., Nasonov E.L. Effect of metformin on the clinical course of gout and insulin resistance. Klin. Med. (Mosk.) 2009;87:41–46.
    1. Juraschek S.P., Plante T.B., Charleston J., Miller E.R., Yeh H.C., Appel L.J., Jerome G.J., Gayles D., Durkin N., White K., et al. Use of online recruitment strategies in a randomized trial of cancer survivors. Clin. Trials. 2018;15:130–138. doi: 10.1177/1740774517745829.
    1. Levey A.S., Stevens L.A., Schmid C.H., Zhang Y., Castro A.F., III, Feldman H.I., Kusek J.W., Eggers P., Van Lente F., Greene T., et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 2009;150:604–612. doi: 10.7326/0003-4819-150-9-200905050-00006.
    1. Baron R.M., Kenny D.A. The Moderator-Mediator Variable Distinction in Social Psychological Research: Conceptual, Strategic, and Statistical Considerations. J. Personal. Soc. Psychol. 1986;51:1173–1182. doi: 10.1037/0022-3514.51.6.1173.
    1. Choi H.K., McCormick N., Lu N., Rai S.K., Yokose C., Zhang Y. Population Impact Attributable to Modifiable Risk Factors for Hyperuricemia. Arthritis Rheumatol. 2020;72:157–165. doi: 10.1002/art.41067.
    1. McCormick N., Rai S.K., Lu N., Yokose C., Curhan G.C., Choi H.K. Estimation of Primary Prevention of Gout in Men Through Modification of Obesity and Other Key Lifestyle Factors. JAMA Netw. Open. 2020;3:e2027421. doi: 10.1001/jamanetworkopen.2020.27421.
    1. Friedman J.E., Dallal R.M., Lord J.L. Gouty attacks occur frequently in postoperative gastric bypass patients. Surg. Obes. Relat. Dis. 2008;4:11–13. doi: 10.1016/j.soard.2007.09.012.
    1. Mandal A.K., Mount D.B. The Molecular Physiology of Uric Acid Homeostasis. Annu. Rev. Physiol. 2015;77:323–345. doi: 10.1146/annurev-physiol-021113-170343.
    1. Juraschek S.P., Kovell L.C., Miller E.R., Gelber A.C. Association of kidney disease with prevalent gout in the United States in 1988–1994 and 2007–2010. Semin. Arthritis Rheum. 2013;42:551–561. doi: 10.1016/j.semarthrit.2012.09.009.
    1. Krikken J.A., Lely A.T., Bakker S.J.L., Navis G. The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men. Kidney Int. 2007;71:260–265. doi: 10.1038/sj.ki.5002011.
    1. Todd A.S., Walker R.J., MacGinley R.J., Kelly J., Merriman T.R., Major T.J., Johnson R.J. Dietary Sodium Modifies Serum Uric Acid Concentrations in Humans. Am. J. Hypertens. 2017;30:1196–1202. doi: 10.1093/ajh/hpx123.
    1. Bobulescu I.A., Moe O.W. Renal Transport of Uric Acid: Evolving Concepts and Uncertainties. Adv. Chronic. Kidney Dis. 2012;19:358–371. doi: 10.1053/j.ackd.2012.07.009.
    1. Boner G., Rieselbach R.E. The effect of glucose upon reabsorptive transport of urate by the kidney. Adv. Exp. Med. Biol. 1974;41:781–787.
    1. Christensen P.J., Steenstrup O.R. Uric acid excretion with increasing plasma glucose concentration (pregnant and non-pregnant cases) Scand. J. Clin. Lab. Investig. 1958;10:182–185. doi: 10.3109/00365515809079942.
    1. Herman J.B., Keynan A. Hyperglycemia and uric acid. Isr. J. Med. Sci. 1969;5:1048–1052.
    1. Facchini F., Chen Y.D., Hollenbeck C.B., Reaven G.M. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991;266:3008–3011. doi: 10.1001/jama.1991.03470210076036.
    1. Juraschek S.P., McAdams-Demarco M., Miller E.R., Gelber A.C., Maynard J.W., Pankow J.S., Young H., Coresh J., Selvin E. Temporal relationship between uric acid concentration and risk of diabetes in a community-based study population. Am. J. Epidemiol. 2014;179:684–691. doi: 10.1093/aje/kwt320.
    1. Hussain A., Latiwesh O.B., Ali F., Younis M.Y.G., Alammari J.A. Effects of Body Mass Index, Glycemic Control, and Hypoglycemic Drugs on Serum Uric Acid Levels in Type 2 Diabetic Patients. Cureus. 2018;10:e3158. doi: 10.7759/cureus.3158.
    1. Krzystek-Korpacka M., Patryn E., Kustrzeba-Wojcicka I., Chrzanowska J., Gamian A., Noczynska A. The effect of a one-year weight reduction program on serum uric acid in overweight/obese children and adolescents. Clin. Chem. Lab. Med. 2011;49:915–921. doi: 10.1515/CCLM.2011.130.
    1. Juraschek S.P., Gelber A.C., Choi H.K., Appel L.J., Miller E.R. Effects of the Dietary Approaches To Stop Hypertension (DASH) Diet and Sodium Intake on Serum Uric Acid. Arthritis Rheumatol. 2016;68:3002–3009. doi: 10.1002/art.39813.
    1. Tang O., Miller E.R., Gelber A.C., Choi H.K., Appel L.J., Juraschek S.P. DASH Diet and Change in Serum Uric Acid over Time. Clin. Rheumatol. 2017;36:1413–1417. doi: 10.1007/s10067-017-3613-x.
    1. Khanna D., Fitzgerald J.D., Khanna P.P., Bae S., Singh M.K., Neogi T., Pillinger M.H., Merill J., Lee S., Prakash S., et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64:1431–1446. doi: 10.1002/acr.21772.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir